


Figure S1 SASP increases in multiple organs and tissues of aging mouse model with impaired autophagy. (A) H&E staining of 2-month old and 18-month old mice. Scale bars of brain and adipose, 100 μ m and 20 μ m. Scale bars of muscle, 500 μ m and 100 μ m. (B) Immunohistochemistry (p62 and p16^{INK4a}) and RNA fluorescence in situ hybridization (FISH) of the brain of 2-month old and 18-

6 month old mice. n=8 per group. Scale bars, 20 μ m. (C) Immunohistochemistry (p62 and p16^{INK4a})
7 and RNA fluorescence in situ hybridization (FISH) of the muscle tissue of 2-month old and 18-
8 month old mice. n=8 per group. Scale bars, 20 μ m. (D) and (E) Immunohistochemistry (p62 and
9 p16^{INK4a}) and RNA fluorescence in situ hybridization (FISH) of the adipose tissue of 2-month old
10 and 18-month old mice. n=8 per group. Scale bars, 20 μ m. (F) CCK8 detection of cell viability of
11 human chondrocytes treated with Rapamycin in different concentration. (G) CCK8 detection of cell
12 viability of C28/I2 treated with Rapamycin or not. (H) Western blot detection of p62 and LC3B in
13 C28/I2 treated with 3-MA or not. (I) Western blot detection of p16^{INK4a} and p21 in C28/I2 treated
14 with Rapamycin or not. (J) Quantification of western blot detection of p16^{INK4a}, p21, p62 and LC3B
15 expression in human primary chondrocytes from the damaged cartilage group or the undamaged
16 cartilage group. (K) Quantification of western blot detection of p62 and LC3B in C28/I2 treated
17 with Rapamycin or not. The data are representative of three independent experiments (H and I).

18 *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, mean \pm SD, two-tailed t test.

19

20




21 **Figure S2** Screening circRNAs associated with OA and autophagy. (A) The mRNA expression level
 22 of 15 circRNAs treated with IL-1 β or not in C28/I2. (B) The mRNA expression level of 15 circRNAs
 23 treated with Rapamycin or not in C28/I2. (C) Expression of circPLXNC1 assessed by RT-qPCR in
 24 the nuclear and cytoplasmic fractions of C28/I2. (D) Western blot detection of p16^{INK4a} and p21 in
 25 human primary chondrocytes cultured to P1-4 generation. (E) Quantification of western blot
 26 detection of p16^{INK4a} and p21 in human primary chondrocytes cultured to P1-4 generation. The data
 27 are representative of three independent experiments (D). *p<0.05, **p<0.01, ***p<0.001,
 28

29 ****p<0.0001, mean \pm SD, two-tailed t test.

30

31




32

33 **Figure S3** Effect of sh-circPLXNC1 on ECM. (A) The mRNA expression level of circPLXNC1 in
 34 C28/I2 treated with two types of sh-circPLXNC1 or sh-NC. (B) Chondrogenic matrix deposition
 35 (Alcian Blue staining) of C28/I2, treated with sh-circPLXNC1 or sh-NC, determined by micromass
 36 culture and quantified by ImageJ software. (C) 3D agarose culture of C28/I2 (Alcian blue staining)
 37 showing the thickness of pericellular matrix. Scale bar, 20 μ m. (D) The mRNA expression of
 38 PLXNC1 in C28/I2 treated with two types of sh-circPLXNC1 or sh-NC. (E) The mRNA expression
 39 level of COL2A1, Aggrecan and SOX9 in C28/I2 treated with si-PLXNC1 or si-NC. (F) The mRNA

40 expression level of FUS in C28/I2 treated with two types of si-FUS or si-NC. (G) Sequence
41 alignment of human circPLXNC1 and the mouse circPLXNC1 homolog. (H) Quantification of
42 western blot detection of COL2A1, Aggrecan, SOX9, p16^{INK4a} and p21 in C28/I2 treated with sh-
43 circPLXNC1 or sh-NC. (I) Quantification of western blot detection of p62 and LC3B in C28/I2
44 treated with sh-circPLXNC1 or sh-NC. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, mean ±
45 SD, two-tailed t test.

46

47



48


49 **Figure S4** Effect of miR-130b-5p on ECM and autophagy. (A) The mRNA expression level of
50 COL2A1, Aggrecan and SOX9 in C28/I2 treated with inhibitor-miR-130b-5p or inhibitor-NC. (B)
51 The representative electron microscopy images of C28/I2 treated with inhibitor-miR-130b-5p or
52 inhibitor-NC. Yellow arrowheads indicate autophagosomes. Scale bars, 5 μm and 1 μm. (C)
53 Chondrogenic matrix deposition (Alcian Blue staining) of C28/I2, treated with inhibitor-miR-130b-

54 5p or inhibitor-NC, determined by micromass culture and quantified by ImageJ software. (D) 3D
 55 agarose culture of C28/I2 (Alcian blue staining) showing the thickness of pericellular matrix. (E)
 56 The relative level of miR-130b-5p in human primary chondrocytes cultured to P1 or P4 generation.
 57 (F) The relative level of miR-130b-5p in C28/I2 treated with IL-1 β or not. (G) The mRNA
 58 expression level of circPLXNC1 in C28/I2 treated with mimic-miR-130b-5p or mimic-NC. (H) The
 59 mRNA expression level of circPLXNC1 in C28/I2 treated with inhibitor-miR-130b-5p or inhibitor-
 60 NC. (I) Quantification of western blot detection of COL2A1, Aggrecan, SOX9, p16^{INK4a} and p21 in
 61 C28/I2 treated with mimic-miR-130b-5p and mimic-NC. (J) Quantification of western blot
 62 detection of COL2A1, Aggrecan, SOX9, p16^{INK4a} and p21 in C28/I2 treated with miR-130b-5p
 63 sponge or NC sponge. (K) Quantification of western blot detection of p62 and LC3B in C28/I2
 64 treated with mimic-miR-130b-5p, mimic-NC, miR-130b-5p sponge or NC sponge. Scale bar, 20 μ m.

65 *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, mean \pm SD, two-tailed t test.

66

67




68

69 **Figure S5** Screen target gene of miR-130b-5p. (A) The mRNA expression level of 6 target genes
 70 treated with IL-1 β or not in C28/I2. (B) The mRNA expression level of 6 target genes treated with
 71 Rapamycin or not in C28/I2. (C) The mRNA expression level of COL2A1, Aggrecan and SOX9 in
 72 C28/I2 treated with si-ATG7 or si-NC. (D) The mRNA expression level of ATG7 in primary cultured
 73 chondrocytes isolated from WT C57BL/6 (B6) mice treated with si mmu-circPLXNC1 or si NC. (E)
 74 The relative level of miR-130b-5p in C28/I2 cultured and transfected with ATG7 or vector. (F)
 75 Quantification of western blot detection of ATG7 in C28/I2 treated with sh-circPLXNC1, sh-NC,
 76 mimic-miR-130b-5p, mimic-NC, miR-130b-5p sponge or NC sponge. *p<0.05, **p<0.01,
 77 ***p<0.001, ****p<0.0001, mean \pm SD, two-tailed t test.

78

79



80

81 **Figure S6** Overexpressing ATG7 partially alleviated senescence and OA progression. (A)
 82 Quantification of western blot detection of COL2A1, Aggrecan, SOX9, p16^{INK4a}, p21 and ATG7 in

83 C28/I2 cultured and transfected with sh-circPLXNC1 (or sh-NC) and ATG7 (or vector). (A)

84 Quantification of western blot detection of p62 and LC3B in C28/I2 cultured and transfected with

85 sh-circPLXNC1 (or sh-NC) and ATG7 (or vector). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001,

86 mean \pm SD, two-tailed t test.